Anti-CXCR2 antibodies and uses thereof
US12018084B2 · kind B2 · utility
0Cited by
2References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2022 |
| Grant date | Jun 25, 2024 |
| Priority date | — |
| Expiry date | Sep 22, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.